CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Bremelanotide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04179734
NCT04179734Phase 4Completed
CompareCT.gov

Physiological Study to Determine the Role of the Melanocortin-4 Receptor in Brain Activity in Women With Hypoactive Sexual Desire Disorder

Imperial College Healthcare NHS Trust·interventional·Posted Nov 27, 2019·Updated Aug 9, 2024

In Brief

A Phase 4 clinical trial evaluating Bremelanotide and Placebo for Hypoactive Sexual Desire Disorder. Completed, enrolled 40 participants across 1 site.

Detailed Summary

A randomised, double-blind, placebo-controlled, two-way crossover physiological study. Designed to evaluate the effects of melanocortin-4 receptor (MC4R) activation on brain activity patterns and behavioural psychometric measures of sexual arousal during visual erotic stimuli in approximately 40 right-handed, heterosexual, premenopausal women aged 18 years and over with Hypoactive Sexual Desire Disorder (HSDD) for at least a 6 month duration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoactive Sexual Desire Disorder
CountriesUnited Kingdom
CollaboratorsAMAG Pharmaceuticals, Inc.

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedNov 27, 2019
Enrollment StartOct 7, 2019
Primary CompletionOct 6, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.6 years ago

Interventions

Bremelanotidedrug

Melanocortin-4 receptor agonist subcutaneous injection.

Placebodrug

Placebo subcutaenous injection.